Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ICPT | Intercept Pharmaceuticals, Inc.

Index	RUT	P/E	-	EPS (ttm)	-4.35	Insider Own	0.60%	Shs Outstand	41.73M	Perf Week	-8.47%
Market Cap	442.47M	Forward P/E	4.58	EPS next Y	2.29	Insider Trans	0.00%	Shs Float	40.48M	Perf Month	1.85%
Income	-158.80M	PEG	-	EPS next Q	-0.44	Inst Own	80.60%	Short Float / Ratio	25.69% / 11.27	Perf Quarter	-10.73%
Sales	306.50M	P/S	1.44	EPS this Y	-20.90%	Inst Trans	15.20%	Short Interest	10.40M	Perf Half Y	-22.88%
Book/sh	1.62	P/B	6.47	EPS next Y	277.50%	ROA	39.70%	Target Price	14.58	Perf Year	-41.32%
Cash/sh	9.80	P/C	1.07	EPS next 5Y	-8.89%	ROE	248.80%	52W Range	8.82 - 21.86	Perf YTD	-15.28%
Dividend	-	P/FCF	-	EPS past 5Y	18.50%	ROI	-37.60%	52W High	-52.06%	Beta	1.20
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	16.90%	Gross Margin	99.70%	52W Low	18.80%	ATR	0.53
Employees	341	Current Ratio	2.50	Sales Q/Q	16.60%	Oper. Margin	-51.80%	RSI (14)	42.43	Volatility	4.56% 4.75%
Optionable	Yes	Debt/Eq	4.94	EPS Q/Q	79.60%	Profit Margin	68.10%	Rel Volume	1.42	Prev Close	10.80
Shortable	Yes	LT Debt/Eq	3.31	Earnings	Aug 02 BMO	Payout	0.00%	Avg Volume	922.63K	Price	10.48
Recom	2.70	SMA20	-5.34%	SMA50	-2.77%	SMA200	-25.45%	Volume	1,313,007	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-23	Upgrade	H.C. Wainwright	Sell → Buy	$8 → $19
Jun-29-23	Upgrade	Canaccord Genuity	Hold → Buy	$12 → $18
May-23-23	Downgrade	Needham	Buy → Hold
May-22-23	Downgrade	H.C. Wainwright	Neutral → Sell	$8
May-17-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-11-22	Upgrade	B. Riley Securities	Neutral → Buy	$25 → $30
Aug-20-21	Downgrade	Goldman	Neutral → Sell	$17 → $10
May-25-21	Downgrade	B. Riley Securities	Buy → Neutral	$18
Mar-12-21	Upgrade	H.C. Wainwright	Sell → Neutral	$21
Feb-23-21	Downgrade	H.C. Wainwright	Neutral → Sell	$25
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform	$40 → $27
Dec-21-20	Downgrade	Jefferies	Buy → Hold	$30
Nov-10-20	Upgrade	Robert W. Baird	Neutral → Outperform	$52
Nov-10-20	Upgrade	Raymond James	Mkt Perform → Outperform	$60
Jul-31-20	Initiated	Piper Sandler	Overweight	$82
Jul-21-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-30-20	Upgrade	Citigroup	Neutral → Buy
Jun-30-20	Downgrade	UBS	Buy → Neutral	$135 → $57
Jun-30-20	Downgrade	Robert W. Baird	Outperform → Neutral	$52
Jun-30-20	Downgrade	Credit Suisse	Outperform → Neutral	$137 → $59

Show Previous Ratings

Sep-08-23 11:59AM	Why CymaBay Therapeutics Stock Is Jumping Today (Motley Fool) +5.54%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Sep-05-23 08:30AM	Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences (GlobeNewswire) -6.84%
Sep-01-23 11:31AM	Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report? (Zacks)
Aug-02-23 10:30AM	Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
08:25AM	Loading…
08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:18AM	Intercept: Q2 Earnings Snapshot (AP Finance)
07:00AM	Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-26-23 10:02AM	Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023 (GlobeNewswire)
Jun-29-23 09:02AM	Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates (Zacks)
Jun-26-23 12:49PM	Intercept (ICPT) to Restructure Operations, Cut Workforce (Zacks)
Jun-23-23 04:06PM	Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug (Investor's Business Daily)
11:54AM	Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA (Zacks)
06:30AM	Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses (GlobeNewswire)
02:45AM	Loading…
02:45AM	Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage (GlobeNewswire)
Jun-22-23 05:56PM	UPDATE 2-US FDA declines to approve Intercept's fatty liver disease drug (Reuters)
05:47PM	US FDA declines to approve Intercept's fatty liver disease drug (Reuters)
05:45PM	Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH (GlobeNewswire)
Jun-18-23 09:41PM	Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
Jun-07-23 04:20PM	New Data Shows Intercept's Fixed Dose Obeticholic Acid Combo Normalize Multiple Biomarkers In Liver Disease (Benzinga) +5.84%
02:42PM	Intercept (ICPT) Announces Positive Data From PBC Study (Zacks)
07:00AM	Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 (GlobeNewswire)
Jun-01-23 06:58AM	Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Shift From Loss To Profit (Simply Wall St.)
May-31-23 08:00AM	Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023 (GlobeNewswire)
May-25-23 10:32AM	Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates (Zacks) +6.32%
May-24-23 01:17PM	Why Madrigal Pharmaceuticals Stock Is Marching Higher Today (Motley Fool)
May-23-23 04:01AM	4 big analyst cuts: Apple loses buy rating on slack iPhone demand (Investing.com)
May-22-23 04:05PM	Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug (Investor's Business Daily) -29.72%
12:55PM	Loading…
12:55PM	NASH Drugs Suffer Another Blow, but Hope Remains (Barrons.com)
12:02PM	Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation (Zacks)
10:46AM	Intercept Pharma Stock Tumbles: FDA Panel Votes Against Intercept's Fatty Liver Drug, Dashing Its Dreams To Enter NASH Space (Benzinga)
May-19-23 06:45PM	Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH (GlobeNewswire)
04:59PM	UPDATE 3-US FDA panel votes against approval of Intercept fatty liver drug, cites safety issues (Reuters)
04:44PM	US FDA panel votes against accelerated approval of Intercept fatty liver drug (Reuters)
07:05AM	Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH (GlobeNewswire)
May-18-23 12:12PM	Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment (Zacks)
02:23AM	4 big analyst cuts: Nu slashed at Citi, Futu gets 2 downgrades (Investing.com)
May-17-23 02:54PM	Why Intercept Pharmaceuticals Shares Are Plunging Today (Benzinga) -14.68%
02:19PM	Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag (Zacks)
09:13AM	US FDA staff flag liver damage concerns about Intercept's NASH treatment (Reuters)
May-16-23 05:00PM	Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC) (GlobeNewswire)
May-12-23 11:06AM	Intercept (ICPT) Gains 26.2% YTD: What's in Store? (Zacks)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-05-23 06:19AM	Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Low P/S No Reason For Excitement (Simply Wall St.)
Apr-27-23 03:49PM	Why Intercept Pharmaceuticals Stock Plunged Today (Motley Fool) -12.92%
08:25AM	Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH (GlobeNewswire)
06:55AM	Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program (GlobeNewswire)
Apr-20-23 10:03AM	Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-18-23 04:04PM	Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout (Investor's Business Daily) +5.27%
05:58AM	Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength? (Zacks)
Apr-13-23 08:00AM	Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023 (GlobeNewswire) +5.87%
Apr-11-23 03:36AM	Intercept (ICPT) Moves 15.0% Higher: Will This Strength Last? (Zacks) +5.20%
Mar-30-23 05:22PM	Top Healthcare Stocks for April 2023 (Investopedia)
Mar-13-23 10:26AM	Intercept (ICPT) Stock Down on FDA Committee Update on NDA (Zacks)
Mar-11-23 09:22AM	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) down to US$672m market cap, but institutional owners may not be as affected after a year of 8.0% returns (Simply Wall St.)
Mar-10-23 04:08PM	Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle (Investor's Business Daily) -13.93%
12:01PM	Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months (Zacks)
09:05AM	Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH (GlobeNewswire)
Mar-09-23 08:00AM	Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023 (GlobeNewswire)
Mar-06-23 05:59AM	Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 11:08AM	Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase (Zacks)
01:09AM	Q4 2022 Intercept Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 08:55AM	Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance (GlobeNewswire)
Feb-27-23 10:00AM	Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:00AM	Intercept Pharmaceuticals to Participate in Cowens 43rd Annual Health Care Conference on March 7, 2023 (GlobeNewswire)
Feb-23-23 10:50AM	13 High Growth Pharma Stocks that are Profitable (Insider Monkey)
08:00AM	Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023 (GlobeNewswire)
Feb-22-23 10:00AM	Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-13-23 04:55PM	Inside the NASH drug boom: New drugs for a silent liver disease that affects millions near FDA approval (MarketWatch)
Jan-25-23 04:06PM	Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years (Investor's Business Daily) +14.36%
Jan-20-23 09:55AM	Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect? (Zacks)
09:53AM	Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA (Zacks)
Jan-19-23 08:00AM	FDA Accepts Intercepts New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH (GlobeNewswire)
Jan-13-23 11:41AM	Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why (Zacks)
Jan-05-23 08:00AM	Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023 (GlobeNewswire) +5.60%
Jan-04-23 09:00AM	Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 (GlobeNewswire)
Dec-23-22 07:50AM	Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH (GlobeNewswire) -12.18%
Dec-20-22 11:15AM	Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study (Zacks) +5.11%
Dec-19-22 04:08PM	Madrigal Pharmaceuticals Stock More Than Doubles on NASH Breakthrough (Barrons.com) -23.47%
01:33PM	Madrigal Pharmaceuticals Hits the NASH Jackpot. Its Stock Is Up 240%. (Barrons.com)
Dec-08-22 06:00PM	New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease (GlobeNewswire)
Dec-05-22 08:29AM	Analysts Expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) To Breakeven Soon (Simply Wall St.)
Dec-01-22 11:31AM	Why Is Intercept (ICPT) Down 3.9% Since Last Earnings Report? (Zacks)
Nov-22-22 08:00AM	Intercept Pharmaceuticals to Participate in Piper Sandlers 34th Annual Healthcare Conference on December 1, 2022 (GlobeNewswire)
Nov-08-22 07:37AM	Intercept Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-07-22 06:55PM	Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis (GlobeNewswire)
08:00AM	Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Nov-06-22 08:00AM	Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Nov-02-22 11:38AM	Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised (Zacks)
Nov-01-22 12:09PM	Why Intercept Pharmaceuticals Stock Is Soaring Today (Motley Fool) +13.41%
08:15AM	Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-22 04:05PM	Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022 (GlobeNewswire)
Oct-30-22 10:40AM	Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested three years ago (Simply Wall St.)
Oct-26-22 10:01AM	Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline (Zacks)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ICPT | Intercept Pharmaceuticals, Inc.

Upgrade your FINVIZ experience